Stoke Therapeutics price target lowered to $35 from $70 at H.C. Wainwright

H.C. Wainwright analyst Andrew Fein lowered the firm’s price target on Stoke Therapeutics to $35 from $70 and keeps a Buy rating on the shares. The analyst says the median reduction of 55% in seizure frequency in a small number of patients shows Stoke is moving in the right direction.